Edition:
United States

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

17.37USD
15 Dec 2017
Change (% chg)

$-0.23 (-1.31%)
Prev Close
$17.60
Open
$17.51
Day's High
$17.58
Day's Low
$17.07
Volume
546,762
Avg. Vol
144,873
52-wk High
$21.35
52-wk Low
$4.74

Chart for

About

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $535.00
Shares Outstanding(Mil.): 30.80
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Uniqure Q3 loss per share $0.40

* Uniqure announces third quarter 2017 financial results and recent company progress

Nov 01 2017

BRIEF-UniQure reports Q3 loss $0.40/shr

* UniQure announces third quarter 2017 financial results and recent company progress

Nov 01 2017

BRIEF-Uniqure announces proposed public offering

* Uniqure NV - ‍ commenced an underwritten public offering of 5 million of its ordinary shares Source text for Eikon: Further company coverage:

Oct 23 2017

BRIEF-uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX

* uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua) Source text for Eikon: Further company coverage:

Oct 19 2017

BRIEF-Uniqure announces AMT-061 to enter pivotal study in 2018

* Uniqure announces Hemophilia B gene therapy program to enter pivotal study with FIX-Padua variant in 2018

Oct 19 2017

BRIEF-Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease

* Uniqure announces FDA orphan drug designation for AMT-130 in huntington’s disease Source text for Eikon: Further company coverage:

Oct 06 2017

BRIEF-Uniqure NV Q2 revenue $4.9 million

* Uniqure announces second quarter 2017 financial results and recent company progress

Aug 08 2017

BRIEF-Uniqure NV - ‍Scott Mcmillan named chief operating officer

* Uniqure announces leadership team appointments and nominations to its board of directors

Aug 07 2017

BRIEF-Uniqure reacquires development and commercialization rights for gene therapy candidate in Hemophilia B

* Uniqure reacquires development and commercialization rights for its gene therapy candidate in Hemophilia B

Jul 31 2017

BRIEF-uniQure reacquires development and commercialization rights for its gene therapy candidate in hemophilia B

* uniQure reacquires development and commercialization rights for its gene therapy candidate in hemophilia B

Jul 31 2017

Earnings vs. Estimates